Atorvastatin Calcium Tablets (Lipitor) is a selective, competitive HMG-CoA reductase inhibitor indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. As a prescription medication, its clinical use must strictly adhere to contraindications, drug interactions, and the principle of individualized therapy, with systematic monitoring to ensure efficacy.

What are the Precautions for Taking Atorvastatin Calcium Tablets (Lipitor)?

Contraindications and Prohibited Populations

Patients with hypersensitivity to atorvastatin calcium or any of its components.

Patients with severe hepatic impairment (e.g., acute hepatitis, acute exacerbation of chronic hepatitis, cirrhosis, hepatocellular carcinoma, jaundice).

Pregnant women, women of childbearing potential, and lactating women.

Patients currently receiving glecaprevir/pibrentasvir.

Dosage Adjustments for Special Patients

Patients with Hepatic Impairment: Contraindicated in moderate to severe hepatic impairment.

Patients with Renal Impairment: Risk of rhabdomyolysis is increased; enhanced monitoring is required.

Patients with Diabetes Mellitus: May exacerbate glycemic abnormalities; regular monitoring of blood glucose-related indicators is necessary.

Elderly Patients: Due to age-related decline in physiological function, dosage should be carefully evaluated and muscle symptoms monitored.

Cautious Concomitant Medication Combinations

Concomitant use with fibrates (e.g., bezafibrate) or niacin preparations significantly increases the risk of rhabdomyolysis.

Dosage adjustment is required when co-administered with strong CYP3A4 inhibitors (e.g., cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors).

Concomitant use with enzyme inducers (e.g., cimetidine, rifampicin) may reduce efficacy.

Grapefruit juice inhibits CYP3A4; intake should be avoided during treatment.

Medication Monitoring for Atorvastatin Calcium Tablets (Lipitor)

Dynamic Tracking of Efficacy Indicators

During the initial treatment phase and after dosage adjustments, monitor total cholesterol, LDL cholesterol, triglycerides, and HDL cholesterol levels to assess lipid target achievement.

For long-term users, recheck blood lipids every 3–6 months to avoid drug tolerance or failure.

Monitoring of Muscle Symptoms and Creatine Kinase (CK)

Immediately evaluate for rhabdomyolysis if unexplained muscle pain, weakness, or a significant elevation in CK occurs.

High-risk populations (e.g., patients with concurrent renal impairment, hypothyroidism, or hereditary myopathy) require enhanced screening.

Hepatic Function Monitoring

Detect indicators such as AST, ALT, and γ-GTP before treatment and within 12 weeks of initiation; recheck every 6 months after stabilization.

Discontinue the medication if persistent elevation of liver enzymes exceeds 3 times the upper limit of normal.

Metabolic and Hematological Indicators

Monitor changes in blood glucose and HbA1c to alert for new-onset diabetes mellitus.

Conduct regular blood routine examinations to monitor rare adverse reactions such as thrombocytopenia and agranulocytosis.